458 related articles for article (PubMed ID: 33085861)
1. Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis.
Dellon ES; Peterson KA; Murray JA; Falk GW; Gonsalves N; Chehade M; Genta RM; Leung J; Khoury P; Klion AD; Hazan S; Vaezi M; Bledsoe AC; Durrani SR; Wang C; Shaw C; Chang AT; Singh B; Kamboj AP; Rasmussen HS; Rothenberg ME; Hirano I
N Engl J Med; 2020 Oct; 383(17):1624-1634. PubMed ID: 33085861
[TBL] [Abstract][Full Text] [Related]
2. Determination of Biopsy Yield That Optimally Detects Eosinophilic Gastritis and/or Duodenitis in a Randomized Trial of Lirentelimab.
Dellon ES; Gonsalves N; Rothenberg ME; Hirano I; Chehade M; Peterson KA; Falk GW; Murray JA; Gehman LT; Chang AT; Singh B; Rasmussen HS; Genta RM
Clin Gastroenterol Hepatol; 2022 Mar; 20(3):535-545.e15. PubMed ID: 34089846
[TBL] [Abstract][Full Text] [Related]
3. Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial.
Kliewer KL; Murray-Petzold C; Collins MH; Abonia JP; Bolton SM; DiTommaso LA; Martin LJ; Zhang X; Mukkada VA; Putnam PE; Kellner ES; Devonshire AL; Schwartz JT; Kunnathur VA; Rosenberg CE; Lyles JL; Shoda T; Klion AD; Rothenberg ME
Lancet Gastroenterol Hepatol; 2023 Sep; 8(9):803-815. PubMed ID: 37336228
[TBL] [Abstract][Full Text] [Related]
4. Siglec-8 antibody reduces eosinophils and mast cells in a transgenic mouse model of eosinophilic gastroenteritis.
Youngblood BA; Brock EC; Leung J; Falahati R; Bochner BS; Rasmussen HS; Peterson K; Bebbington C; Tomasevic N
JCI Insight; 2019 Oct; 4(19):. PubMed ID: 31465299
[TBL] [Abstract][Full Text] [Related]
5. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
Castro M; Wenzel SE; Bleecker ER; Pizzichini E; Kuna P; Busse WW; Gossage DL; Ward CK; Wu Y; Wang B; Khatry DB; van der Merwe R; Kolbeck R; Molfino NA; Raible DG
Lancet Respir Med; 2014 Nov; 2(11):879-890. PubMed ID: 25306557
[TBL] [Abstract][Full Text] [Related]
6. AK002, a Humanized Sialic Acid-Binding Immunoglobulin-Like Lectin-8 Antibody that Induces Antibody-Dependent Cell-Mediated Cytotoxicity against Human Eosinophils and Inhibits Mast Cell-Mediated Anaphylaxis in Mice.
Youngblood BA; Brock EC; Leung J; Falahati R; Bryce PJ; Bright J; Williams J; Shultz LD; Greiner DL; Brehm MA; Bebbington C; Tomasevic N
Int Arch Allergy Immunol; 2019; 180(2):91-102. PubMed ID: 31401630
[TBL] [Abstract][Full Text] [Related]
7. Discovery, Function, and Therapeutic Targeting of Siglec-8.
Youngblood BA; Leung J; Falahati R; Williams J; Schanin J; Brock EC; Singh B; Chang AT; O'Sullivan JA; Schleimer RP; Tomasevic N; Bebbington CR; Bochner BS
Cells; 2020 Dec; 10(1):. PubMed ID: 33374255
[TBL] [Abstract][Full Text] [Related]
8. An anti-siglec-8 antibody depletes sputum eosinophils from asthmatic subjects and inhibits lung mast cells.
Kerr SC; Gonzalez JR; Schanin J; Peters MC; Lambrecht BN; Brock EC; Charbit A; Ansel KM; Youngblood BA; Fahy JV
Clin Exp Allergy; 2020 Aug; 50(8):904-914. PubMed ID: 32542913
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
[TBL] [Abstract][Full Text] [Related]
10. Sialic acid-binding immunoglobulin-like lectin (Siglec) 8 in patients with eosinophilic disorders: Receptor expression and targeting using chimeric antibodies.
Legrand F; Cao Y; Wechsler JB; Zhu X; Zimmermann N; Rampertaap S; Monsale J; Romito K; Youngblood BA; Brock EC; Makiya MA; Tomasevic N; Bebbington C; Maric I; Metcalfe DD; Bochner BS; Klion AD
J Allergy Clin Immunol; 2019 Jun; 143(6):2227-2237.e10. PubMed ID: 30543818
[TBL] [Abstract][Full Text] [Related]
11. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Ferguson GT; FitzGerald JM; Bleecker ER; Laviolette M; Bernstein D; LaForce C; Mansfield L; Barker P; Wu Y; Jison M; Goldman M;
Lancet Respir Med; 2017 Jul; 5(7):568-576. PubMed ID: 28545978
[TBL] [Abstract][Full Text] [Related]
12. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial.
Diver S; Khalfaoui L; Emson C; Wenzel SE; Menzies-Gow A; Wechsler ME; Johnston J; Molfino N; Parnes JR; Megally A; Colice G; Brightling CE;
Lancet Respir Med; 2021 Nov; 9(11):1299-1312. PubMed ID: 34256031
[TBL] [Abstract][Full Text] [Related]
13. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials.
Bernstein JA; Virchow JC; Murphy K; Maspero JF; Jacobs J; Adir Y; Humbert M; Castro M; Marsteller DA; McElhattan J; Hickey L; Garin M; Vanlandingham R; Brusselle G
Lancet Respir Med; 2020 May; 8(5):461-474. PubMed ID: 32066536
[TBL] [Abstract][Full Text] [Related]
14. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.
Wechsler ME; Akuthota P; Jayne D; Khoury P; Klion A; Langford CA; Merkel PA; Moosig F; Specks U; Cid MC; Luqmani R; Brown J; Mallett S; Philipson R; Yancey SW; Steinfeld J; Weller PF; Gleich GJ;
N Engl J Med; 2017 May; 376(20):1921-1932. PubMed ID: 28514601
[TBL] [Abstract][Full Text] [Related]
15. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
Harrison TW; Chanez P; Menzella F; Canonica GW; Louis R; Cosio BG; Lugogo NL; Mohan A; Burden A; McDermott L; Garcia Gil E; Zangrilli JG;
Lancet Respir Med; 2021 Mar; 9(3):260-274. PubMed ID: 33357499
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β
Bleecker ER; FitzGerald JM; Chanez P; Papi A; Weinstein SF; Barker P; Sproule S; Gilmartin G; Aurivillius M; Werkström V; Goldman M;
Lancet; 2016 Oct; 388(10056):2115-2127. PubMed ID: 27609408
[TBL] [Abstract][Full Text] [Related]
17. Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis.
Dellon ES; Rothenberg ME; Collins MH; Hirano I; Chehade M; Bredenoord AJ; Lucendo AJ; Spergel JM; Aceves S; Sun X; Kosloski MP; Kamal MA; Hamilton JD; Beazley B; McCann E; Patel K; Mannent LP; Laws E; Akinlade B; Amin N; Lim WK; Wipperman MF; Ruddy M; Patel N; Weinreich DR; Yancopoulos GD; Shumel B; Maloney J; Giannelou A; Shabbir A
N Engl J Med; 2022 Dec; 387(25):2317-2330. PubMed ID: 36546624
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study.
Cellier C; Bouma G; van Gils T; Khater S; Malamut G; Crespo L; Collin P; Green PHR; Crowe SE; Tsuji W; Butz E; Cerf-Bensussan N; Macintyre E; Parnes JR; Leon F; Hermine O; Mulder CJ;
Lancet Gastroenterol Hepatol; 2019 Dec; 4(12):960-970. PubMed ID: 31494097
[TBL] [Abstract][Full Text] [Related]
19. Biologics in eosinophilic gastrointestinal diseases.
Dellon ES; Spergel JM
Ann Allergy Asthma Immunol; 2023 Jan; 130(1):21-27. PubMed ID: 35738437
[TBL] [Abstract][Full Text] [Related]
20. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial.
Gonem S; Berair R; Singapuri A; Hartley R; Laurencin MFM; Bacher G; Holzhauer B; Bourne M; Mistry V; Pavord ID; Mansur AH; Wardlaw AJ; Siddiqui SH; Kay RA; Brightling CE
Lancet Respir Med; 2016 Sep; 4(9):699-707. PubMed ID: 27503237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
